Dr. Lal PathLabs expands through genomics and Dubai unit

Dr. Lal PathLabs Limited expanded its diagnostics footprint in the six months ended 30 September 2026, acquiring Shahbazkers Diagnostic Centre Private Limited for Rs 20 crore, incorporating a Dubai subsidiary with AED 19 million of capital and completing a 70% SN Gene acquisition on 1 October for up to Rs 168 crore plus an earn-out.

What acquisitions did Dr. Lal PathLabs complete in 2026?

Dr. Lal PathLabs acquired 100% of Shahbazkers Diagnostic Centre Private Limited on 1 May 2026 for Rs 20 crore in cash, making the diagnostics and healthcare-services provider a wholly owned subsidiary. The transaction was completed under a share purchase agreement during the six months ended 30 September 2026.

Dr. Lal PathLabs also completed the acquisition of a 70% stake in SN Genelab Private Limited, referred to by the Company as SN Gene, on 1 October 2026. The Board approved the transaction on 24 September 2026, and SN Gene became a subsidiary after the 30 September reporting date; its business is diagnostics-genomics services.

The SN Gene terms provide for cash consideration of up to Rs 168 crore and a performance-linked earn-out capped at Rs 31.5 crore. This differs from the Shahbazkers transaction, which gave Dr. Lal PathLabs complete ownership for a stated Rs 20 crore cash consideration without a disclosed earn-out component.

How is Dr. Lal PathLabs establishing a Dubai presence?

Dr. Lal PathLabs incorporated Dr Lal Pathlabs FZCO as a wholly owned subsidiary in Dubai, United Arab Emirates, during the six months ended 30 September 2026. The Company subscribed to 19,135 equity shares at AED 1,000 each, representing total consideration of AED 19 million.

The filing identifies the Dubai incorporation and AED 19 million share subscription, but it does not disclose a diagnostic-service launch date, revenue target or service menu for Dr Lal Pathlabs FZCO. The announcement therefore establishes the overseas legal entity and its initial subscribed capital rather than an operating forecast.

During the same six-month period, Dr. Lal PathLabs made an additional Rs 7.75 crore equity investment in its wholly owned subsidiary Dr. Lal Ventures Private Limited. The filing describes this as a subscription for additional equity shares and does not state a related acquisition target or operating programme for Dr. Lal Ventures.

The overseas incorporation occurred alongside the Company’s domestic transactions, including the Rs 20 crore Shahbazkers acquisition and the approved SN Gene transaction of up to Rs 168 crore. However, the filing does not connect the AED 19 million Dubai investment to a particular laboratory, customer contract or diagnostics category.

How did Dr. Lal PathLabs gain full ownership of Centrapath Labs?

Centrapath Labs Private Limited became wholly owned by Pathlabs Unifiers Private Limited after Pathlabs Unifiers acquired its remaining 30% stake for Rs 30.3 crore. The Company disclosed that this occurred subsequent to 30 September 2026, following an additional Rs 30.3 crore investment by Dr. Lal PathLabs in Pathlabs Unifiers.

The structure was indirect: Dr. Lal PathLabs subscribed to additional equity shares in Pathlabs Unifiers Private Limited, or PUPL, and PUPL used the funds to acquire the outstanding Centrapath Labs Private Limited, or CPL, stake. The filing does not provide a specific completion date beyond saying the investment and acquisition were subsequent to 30 September 2026.

The CPL transaction contrasts with the 1 May 2026 Shahbazkers deal in both structure and ownership position. Dr. Lal PathLabs directly acquired 100% of Shahbazkers for Rs 20 crore, while PUPL used Rs 30.3 crore of parent funding to purchase the final 30% of CPL and make it a wholly owned subsidiary of PUPL.

The Company also records Rs 70 crore of investment in subsidiaries in its standalone cash-flow statement for the six months ended 30 September 2026. That aggregate cash-flow line is not allocated among Shahbazkers, Dr. Lal Ventures, the Dubai subsidiary or other subsidiary investments in the filing.

How did Dr. Lal PathLabs perform during the expansion period?

Dr. Lal PathLabs reported standalone revenue from operations of Rs 1,596.5 crore for the six months ended 30 September 2026, compared with Rs 1,340.3 crore in the corresponding 2025 period. Standalone profit for the period rose to Rs 345.6 crore from Rs 275 crore over the same comparison.

Standalone net cash generated by operating activities increased to Rs 387 crore from Rs 307.6 crore in the prior-year six-month period. The same cash-flow statement shows net cash used in investing activities of Rs 177 crore for the 2026 period, compared with Rs 377.2 crore in the comparable 2025 period.

Dr. Lal PathLabs reports no reportable operating segments because its Board, identified as the chief operating decision maker, evaluates performance and allocates resources as a single unit under Indian Accounting Standard 108, or Ind AS 108. Consequently, the filing does not separately report revenue, profit or assets for Shahbazkers, SN Gene, Dr Lal Pathlabs FZCO or CPL as at 30 September 2026.

Conclusion

The disclosed transactions show Dr. Lal PathLabs expanding through several structures in 2026: direct full ownership of Shahbazkers for Rs 20 crore, a 70% position in genomics-services provider SN Gene for up to Rs 168 crore, AED 19 million of subscribed capital for a Dubai subsidiary, and indirect full ownership of CPL through Rs 30.3 crore of funding to PUPL. These actions were disclosed alongside a rise in standalone six-month revenue to Rs 1,596.5 crore and profit to Rs 345.6 crore.

The next disclosed item to watch is the performance-linked SN Gene earn-out, which is capped at Rs 31.5 crore and depends on performance. The filing also leaves unresolved the operating timetable, services and revenue plan for Dr Lal Pathlabs FZCO, while confirming that SN Gene became a subsidiary on 1 October 2026, after the 30 September reporting date.